Beacon Pointe Advisors LLC bought a new position in Incyte Corporation (NASDAQ: INCY) in the second

MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-Am

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized ba

Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy ratin

Pre-Market Stock Futures: Futures are trading lower after a wild day on Wall Street, as stocks took

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises

MECHANICSBURG, Pa.--(BUSINESS WIRE)--The Global Vitiligo Foundation (GVF) proudly recognizes and sup

Biopharmaceutical company Incyte Corporation (INCY) gets Big Money support to gain 23% so far in 202

Cetera Investment Advisers trimmed its position in Incyte Corporation (NASDAQ: INCY) by 18.7% in the

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing R

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider

Mizuho analyst Salim Syed maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price t

Top Wall Street analysts changed their outlook on top names. Barclays raised DAR's target to $65

Leerink Partners analyst Andrew Berens maintains Incyte (NASDAQ:INCY) with a Outperform and raise

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

MinjuvI (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemoth

Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemoth

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raise

Incyte Corp. (INCY) reported strong Q2 results, raised full-year sales guidance. CEO cites sales gro

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:INCY) with a Market Perform and raise

RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high

Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the pri

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Incyte (NASDAQ:INCY) with a Buy and

The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Fre

Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance ra

Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the com

Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed

Incyte NASDAQ: INCY reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a y

Incyte Corporation ends the first half of 2026 on a high note. Yesterday, its stock reached a 52-wee

Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estim

ServiceNow shares rose 6.9% to settle at $105.56 during the session, while Meta shares fell 0.2% to

Incyte (NASDAQ:INCY) reported quarterly earnings of $3.09 per share which beat the analyst consensus

Incyte (NASDAQ:INCY) raises FY2026 sales outlook from $4.770 billion-$4.940 billion to $5.130 billio

JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price

Morgan Stanley analyst Judah Frommer maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raise

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth I

Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the pri

Incyte reports Phase 1/2 latarcibart data showing lower bleeding rates and favorable safety in patie

BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:INCY) with a Market Perform and raise

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raise

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and